Neximmune and zephyr ai announce a strategic partnership in oncology for target discovery and validation

Gaithersburg, md., march 17, 2022 (globe newswire) -- neximmune, inc. (nasdaq: nexi) and zephyr ai (zephyr) today announced a strategic partnership focusing on the discovery and validation of novel targets for new t-cell-mediated therapies in oncology. combining zephyr's proprietary artificial intelligence (ai) and algorithmic technology with neximmune's artificial immune modulation (aim) nanoparticle technology, the collaboration will seek to identify and validate optimal antigens and antigen cocktails for the development of potential new therapeutics in solid and hematological cancers.
NEXI Ratings Summary
NEXI Quant Ranking